Roberto Caricchio, MD
Rheumatology · Worcester, MANPI 1376708032
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,272 of the $78,550 with a category attached, or 89.5%. 8 manufacturers reported payments, led by AbbVie at 50.9% of the total. 2025 is the largest year on record at $26,571, 4.5 times the $5,945 reported in 2019. Among rheumatology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $1155.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$40K
- GSK$13K
- Merck$9K
- AstraZeneca$8K
- Johnson & Johnson$6K
- Sobi, Inc$3K
- plus $229 from 2 others
Across 43 payments — averaging $66,707 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.3M
- Eli Lilly$179K
- E.r. Squibb & Sons, L.L.C.$114K
- Bristol Myers Squibb$106K
- Janssen Research & Development, LLC$84K
- Astrazeneca UK Limited$44K
- plus $50K from 2 others
What the payments were for
- Consulting fees$70,27289%
- Travel & lodging$6,7369%
- Food & beverage$1,5412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $39,950 |
| GSK | 9 | $12,833 |
| Merck | 6 | $8,658 |
| AstraZeneca | 11 | $7,933 |
| Johnson & Johnson | 8 | $5,945 |
| Sobi, Inc | 1 | $3,000 |
| Novartis | 2 | $204 |
| Amgen | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$9,522
- SAPHNELO$7,698
- SIMPONI ARIA$5,868
- Kineret$3,000
How this compares
$78,550 in reported general payments places this provider in the 90th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XeljanzTofacitinib Citrate | 12 | $69,763 |
| Mycophenolate Mofetil | 12 | $3,130 |
| Hydroxychloroquine Sulfate | 57 | $2,074 |
| Prednisone | 17 | $117 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Worcester
- Jonathan KayWorcester$191K
- Timothy McAlindonWorcester$129K
- Charles BirbaraWorcester$24K
- Jonathan CheahWorcester$16K
- Leslie HarroldWorcester$16K
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Ronald RapoportFall River$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.